Results you can trust when accuracy is critical, on a platform built for your lab.

Current molecular solutions for influenza testing often require tradeoffs between throughput, lengthy turnaround times, highly complex workflows, and unsustainable costs. Stop compromising. Quidel's Solana Instrument and Solana Influenza A+B Assay offer a scalable and flexible molecular solution for influenza testing that delivers highly accurate molecular results in an actionable timeframe. Results you can trust when accuracy is critical, on a platform built for your lab.

Prompt initiation of patient management and antimicrobial therapy
- Results in just 45 minutes
- High volume throughput capabilities
  Batch up to 12 tests per run

True, Molecular Accuracy
- Gold standard sensitivity
- Confidence in your prescription decision
- Use as a confirmation method for negative rapid results

Ease and Affordability
- Wide range of transport media compatibility
- Simple procedure
- Sustainable reagent pricing
- Flexible instrument placement options

### Procedure

**Sample Preparation**

- **Specimen in transport media**
- **Process Buffer Tube**
- **Reaction Tube**

![Flowchart showing sample preparation process]

**Amplification**

- **95°C for 5 Min.**

**Detection**

- **50 µL**

---

### Time to 12 results

<table>
<thead>
<tr>
<th>Assay Type</th>
<th>Sample Prep/Hands-on Time</th>
<th>Assay Run Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Solana 12 tube chamber</strong></td>
<td>18 min (36 min)</td>
<td>40 min (90 min)</td>
</tr>
<tr>
<td><strong>Real-Time PCR Assays</strong></td>
<td>36 min (15:36 min)</td>
<td>90-120 min (180-240 min)</td>
</tr>
<tr>
<td><strong>CLIA Waived, Single Test MDx System</strong></td>
<td>15:36 min</td>
<td>180-240 min</td>
</tr>
</tbody>
</table>

---

### Clinical Performance

**Performance Characteristics of the Solana Influenza A+B Assay for Influenza A Compared to Culture and DSFA (Across All Sites Combined)**

<table>
<thead>
<tr>
<th>Source Category</th>
<th>N</th>
<th>TP</th>
<th>FP</th>
<th>TN</th>
<th>FN</th>
<th>Sensitivity % (95% CI)</th>
<th>Specificity % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresh</td>
<td>709</td>
<td>180</td>
<td>24</td>
<td>503</td>
<td>2</td>
<td>98.9 (96.1 to 99.7)</td>
<td>95.4 (93.3 to 96.9)</td>
</tr>
<tr>
<td>Frozen</td>
<td>699</td>
<td>176</td>
<td>27</td>
<td>493</td>
<td>3</td>
<td>98.3 (95.2 to 99.4)</td>
<td>94.8 (92.6 to 96.4)</td>
</tr>
<tr>
<td>All</td>
<td>1408</td>
<td>358</td>
<td>51*</td>
<td>996</td>
<td>5**</td>
<td>98.6 (96.8 to 99.4)</td>
<td>95.1 (93.7 to 96.3)</td>
</tr>
</tbody>
</table>

*Of the fifty-one (51) discordant specimens (Solana Positive/Culture and DSFA Negative), twenty-eight (28) of these specimens were positive by an alternate FDA-cleared molecular assay.

**Performance Characteristics of the Solana Influenza A+B Assay for Influenza B Compared to Culture and DSFA (Across All Sites Combined)**

<table>
<thead>
<tr>
<th>Source Category</th>
<th>N</th>
<th>TP</th>
<th>FP</th>
<th>TN</th>
<th>FN</th>
<th>Sensitivity % (95% CI)</th>
<th>Specificity % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresh</td>
<td>709</td>
<td>62</td>
<td>1</td>
<td>646</td>
<td>0</td>
<td>100 (94.2 to 100)</td>
<td>99.8 (99.1 to 100)</td>
</tr>
<tr>
<td>Frozen</td>
<td>699</td>
<td>23</td>
<td>8</td>
<td>668</td>
<td>0</td>
<td>100 (85.7 to 100)</td>
<td>98.8 (97.7 to 99.4)</td>
</tr>
<tr>
<td>All</td>
<td>1408</td>
<td>85</td>
<td>9*</td>
<td>1314</td>
<td>0</td>
<td>100 (95.7 to 100)</td>
<td>99.3 (98.7 to 99.6)</td>
</tr>
</tbody>
</table>

*Of the nine (9) discordant specimens (Solana Positive/Culture and DSFA Negative), two (2) of these specimens were positive by an alternate FDA-cleared molecular assay.

---

---

---

---

---

---

Solana Influenza A+B Assay – 48 Test Kit: Cat. #M300
Solana Influenza A+B Control Set – 20-Reaction Kit: Cat. #M122
Solana Instrument – Cat. #20278